Anti-CCP2 antibodies: An overview and perspective of the diagnostic abilities of this for early rheumatoid arthritis

被引：42

作者：

van Venrooij, Walther J. ^{[1
]}

Zendman, Albert J. W. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Dept Biomol Chem, NL-6525 ED Nijmegen, Netherlands

来源：

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY | 2008年 / 34卷 / 01期

关键词：

autoantibodies; Rheumatoid factor; Anti-cyclic citrullinated peptide; CCP2; test;

D O I：

10.1007/s12016-007-8029-y

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

The literature of the last 4 years confirms that the anti-CCP2 test is a very useful marker for the early and specific diagnosis of rheumatoid arthritis (RA). The antiCCP2 test is very specific for RA (95-99%) and has sensitivity comparable to that of the rheumatoid factor (70-75%). The antibodies can be detected very early in the disease and can be used as an indicator for the progression and prognosis of RA. In this review, these interesting properties and some future possibilities of this diagnostic test are discussed.

引用

页码：36 / 39

页数：4

共 32 条

[1] Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA [J].

Agrawal, Sumeet ;

Misra, Ramnath ;

Aggarwal, Amita .

CLINICAL RHEUMATOLOGY, 2007, 26 (02) :201-204

[2]

Anzilotti C, 2006, J RHEUMATOL, V33, P647

[3] A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis [J].

Berglin, E ;

Padyukov, L ;

Sundin, U ;

Hallmans, G ;

Stenlund, H ;

van Venrooij, WJ ;

Klareskog, L ;

Dahlqvist, SR .

ARTHRITIS RESEARCH & THERAPY, 2004, 6 (04) :R303-R308

[4] Citrullinated proteins in rheumatoid arthritis - Crucial ... but not sufficient! [J].

Cantaert, Tineke ;

De Rycke, Leen ;

Bongartz, Tim ;

Matteson, Eric L. ;

Tak, Paul P. ;

Nicholas, Anthony P. ;

Baeten, Dominique .

ARTHRITIS AND RHEUMATISM, 2006, 54 (11) :3381-3389

[5] Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis [J].

Coenen, Dries ;

Verschueren, Patrick ;

Westhovens, Rene ;

Bossuyt, Xavier .

CLINICAL CHEMISTRY, 2007, 53 (03) :498-504

[6] EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) [J].

Combe, B. ;

Landewe, R. ;

Lukas, C. ;

Bolosiu, H. D. ;

Breedveld, F. ;

Dougados, M. ;

Emery, P. ;

Ferraccioli, G. ;

Hazes, J. M. W. ;

Klareskog, L. ;

Machold, K. ;

Martin-Mola, E. ;

Nielsen, H. ;

Silman, A. ;

Smolen, J. ;

Yazici, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) :34-45

[7] Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis [J].

Dejaco, Christian ;

Klotz, Werner ;

Larcher, Heike ;

Duftner, Christina ;

Schirmer, Michael ;

Herold, Manfred .

ARTHRITIS RESEARCH & THERAPY, 2006, 8 (04)

[8]

Del Val Del Amno N, 2006, CLIN EXP RHEUMATOL, V24, P281

[9]

FRANCH A, 1994, J RHEUMATOL, V21, P489

[10] Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule [J].

Hill, JA ;

Southwood, S ;

Sette, A ;

Jevnikar, AM ;

Bell, DA ;

Cairns, E .

JOURNAL OF IMMUNOLOGY, 2003, 171 (02) :538-541

← 1 2 3 4 →